Comparative Studies of the Proteome, Glycoproteome, and N-Glycome of Clear Cell Renal Cell Carcinoma Plasma before and after Curative Nephrectomy

Gbormittah, Francisca Owusu; Lee, Ling Y.; Taylor, Kyonese; Hancock, William S.; Iliopoulos, Othon

doi:10.1021/pr500591e

Cited by 29 publications

(21 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 In clear cell renal cell carcinoma and prostate cancer, CD146 glycosylation levels were upregulated. 24,25 In 2018, it was reported that CD146 glycosylation is favorably carried out by b-1,3-galactosyl-Oglycosyl-glycoprotein b-1,6-N-acetylglucosaminyltransferase-3, which was overexpressed in highly metastatic melanomas. Such glycosylations can extend CD146 protein stability, upregulate CD146 protein levels, and lead to elevation of CD146-mediated cellular motility in melanoma cells.…”

Section: The Cd146 Proteinmentioning

confidence: 99%

CD146, from a melanoma cell adhesion molecule to a signaling receptor

Wang

Zhang

et al. 2020

Sig Transduct Target Ther

118

View full text Add to dashboard Cite

CD146 was originally identified as a melanoma cell adhesion molecule (MCAM) and highly expressed in many tumors and endothelial cells. However, the evidence that CD146 acts as an adhesion molecule to mediate a homophilic adhesion through the direct interactions between CD146 and itself is still lacking. Recent evidence revealed that CD146 is not merely an adhesion molecule, but also a cellular surface receptor of miscellaneous ligands, including some growth factors and extracellular matrixes. Through the bidirectional interactions with its ligands, CD146 is actively involved in numerous physiological and pathological processes of cells. Overexpression of CD146 can be observed in most of malignancies and is implicated in nearly every step of the development and progression of cancers, especially vascular and lymphatic metastasis. Thus, immunotherapy against CD146 would provide a promising strategy to inhibit metastasis, which accounts for the majority of cancer-associated deaths. Therefore, to deepen the understanding of CD146, we review the reports describing the newly identified ligands of CD146 and discuss the implications of these findings in establishing novel strategies for cancer therapy.

show abstract

Section: The Cd146 Proteinmentioning

confidence: 99%

CD146, from a melanoma cell adhesion molecule to a signaling receptor

Wang

Zhang

et al. 2020

Sig Transduct Target Ther

118

View full text Add to dashboard Cite

show abstract

“… 1 , 2 There are several histological subtypes of RCC due to differences in incidence, biological behavior, and metastasis potential, and ~75% of RCC patients were diagnosed with renal clear cell carcinoma (RCCC), whereas the papillary and chromophobe subtypes contribute 15% and 5%, respectively. 3 , 4 The incidence of RCCC in the People’s Republic of China shows an increasing trend year by year, and RCCC has changeable biological behavior, complex etiology, and poor prognosis, and thus, it is of great importance to study the biological factors in the occurrence and development of RCCC. 5 …”

Section: Introductionmentioning

confidence: 99%

Downregulation of VEGFA inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of renal clear cell carcinoma

Zeng

Huang

et al. 2016

OTT

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to investigate the effects of vascular endothelial growth factor A (VEGFA) on cell proliferation, apoptosis, migration, and invasion in renal clear cell carcinoma (RCCC).MethodsBetween June 2012 and June 2015, RCCC tissues were obtained for the experimental group, and RCCC adjacent tumor-free kidney parenchyma tissues were obtained for the control group. VEGFA mRNA and protein expressions and phosphoinositide 3-kinase, serine/threonine-specific protein kinase (AKT), and phosphorylated-AKT protein expressions were detected. The chemically synthesized specific siRNA using RNA interference technology was used to inhibit VEGFA gene expression in human RCCC 786-O cells. The negative control (NC) group was transfected with NC sequence, and the blank group was transfected with no sequence. Flow cytometry, scratch test, and cell-penetrating experiment were used to detect cell proliferation, apoptosis, migration, and invasion of 786-O cells.ResultsPositive expression of VEGFA protein was 60.62% in RCCC tissue and 18.34% in adjacent tissue with statistically significant difference (P<0.001). VEGFA protein and mRNA expressions were higher in RCCC tissue than those in adjacent tissue (both P<0.01). VEGF expression in RCCC tissue was associated with Fuhrman grading and American Joint Committee on Cancer staging (both P<0.05). After RCCC 786-O cells transfecting the VEGFA siRNA, the VEGFA mRNA and protein expressions and phosphoinositide 3-kinase and phosphorylated-AKT protein expressions were significantly decreased, cell proliferation was remarkably inhibited, cell apoptotic ratio was obviously increased, and migration distance and invasive cell number were markedly decreased compared to those in the NC group and the blank group (all P<0.05).ConclusionInhibition of VEGFA inhibited proliferation, promoted apoptosis, and suppressed migration and invasion of RCCC 786-O cells. VEGF has a potential role in diagnosis and therapy of RCCC.

show abstract

“…Considering many proteins that are secreted or localized to the plasma membrane are N-linked glycosylated, thus having a higher chance of being shed into the extracellular space, multiple studies have included N-linked glycoprotein enrichment strategies for biomarker detection [77]. Gbormittah et al [78] characterized global proteome, N-linked glycoproteome, and N-glycome plasma profiles of RCC patients before and after nephrectomy using a combined approach of immunodepletion and lectin enrichment. The author's global proteomic results revealed several proteins (i.e.…”

Section: Serum/plasma Profilingmentioning

confidence: 99%

Proteomic approaches for characterizing renal cell carcinoma

Clark

Zhang

2020

Clin Proteom

View full text Add to dashboard Cite

Renal cell carcinoma is among the top 15 most commonly diagnosed cancers worldwide, comprising multiple subhistologies with distinct genomic, proteomic, and clinicopathological features. Proteomic methodologies enable the detection and quantitation of protein profiles associated with the disease state and have been explored to delineate the dysregulated cellular processes associated with renal cell carcinoma. In this review we highlight the reports that employed proteomic technologies to characterize tissue, blood, and urine samples obtained from renal cell carcinoma patients. We describe the proteomic approaches utilized and relate the results of studies in the larger context of renal cell carcinoma biology. Moreover, we discuss some unmet clinical needs and how emerging proteomic approaches can seek to address them. There has been significant progress to characterize the molecular features of renal cell carcinoma; however, despite the large-scale studies that have characterized the genomic and transcriptomic profiles, curative treatments are still elusive. Proteomics facilitates a direct evaluation of the functional modules that drive pathobiology, and the resulting protein profiles would have applications in diagnostics, patient stratification, and identification of novel therapeutic interventions.

show abstract

Comparative Studies of the Proteome, Glycoproteome, and N-Glycome of Clear Cell Renal Cell Carcinoma Plasma before and after Curative Nephrectomy

Cited by 29 publications

References 57 publications

CD146, from a melanoma cell adhesion molecule to a signaling receptor

CD146, from a melanoma cell adhesion molecule to a signaling receptor

Downregulation of VEGFA inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of renal clear cell carcinoma

Proteomic approaches for characterizing renal cell carcinoma

Contact Info

Product

Resources

About